Davis Investment Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Davis Investment Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Buy	+1,506	New	+$204K	0.07%	162
2024 Q4	–	Sell	-2,545	Closed	-$250K	–	133
2024 Q3	$250K	Hold	2,545	–	–	0.1%	104
2024 Q2	$252K	Sell	2,545 -525	-17%	-$47.1K	0.1%	101
2024 Q1	$276K	Hold	3,070	–	–	0.12%	94
2023 Q4	$275K	Sell	3,070 -350	-10%	-$26K	0.13%	89
2023 Q3	$247K	Hold	3,420	–	–	0.13%	89
2023 Q2	$288K	Sell	3,420 -500	-13%	-$41.8K	0.14%	91
2023 Q1	$296K	Hold	3,920	–	–	0.16%	84
2022 Q4	$335K	Buy	+3,920	New	+$317K	0.17%	86

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Davis Investment Partners's XBI Position: Q2 2026 in Review

Davis Investment Partners opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 1,506 shares worth $238K. The stake represents 0.07% of the portfolio and ranks #162 among its holdings. This is a return to the name: Davis Investment Partners previously reported a position in XBI as recently as Q3 2024.

Davis Investment Partners first reported a position in XBI in Q4 2022 and has held it in 9 quarters since. The position peaked at $335K in Q4 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Davis Investment Partners held 1,506 shares of State Street SPDR S&P Biotech ETF worth $238K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Davis Investment Partners position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.07% of Davis Investment Partners's portfolio in Q2 2026, its #162 holding.
Davis Investment Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and has held it in 9 quarters since.
Davis Investment Partners's State Street SPDR S&P Biotech ETF position peaked at $335K in Q4 2022.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Davis Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.